- Specializing in Creating Customized IVRs, Voice, SMS, Chat and HIPAA Compliant Secure Message Applications
Specializing in Creating Customized IVRs, Voice, SMS, Chat and HIPAA Compliant Secure Message Applications
When PROMs fall short: making patient-reported outcomes actionable
We are here to help
Healthcare Solutions
If you're in healthcare, you owe it to yourself to learn how you can make your everyday business processes more efficient and save money at the same time. We can help in automating many of your routine and repetitive tasks, including Patient Engagement surveys.
Contact us to learn more
Transportation Solutions
If you're in the transportation business, you can automate many of your routine tasks like package notifications, surveys, collection calls and more. Improve your customer satisfaction by extending your service hours without extending your costs.
Connect with us to learn more
How trial operations can avoid ceiling effects, missing laterality, and inconsistent subscale reporting
Patient-reported outcomes (PROs) are supposed to bring the patient perspective into clinical trials. In practice, choice of instrument and the way results are reported often leave sponsors with data that are hard to interpret. A recent literature review of age-related macular degeneration (AMD) trials found that poor patient-reported outcome measure (PROM) selection and inconsistent baseline and laterality reporting create avoidable ambiguity in study endpoints.
The operational problem is not scholarly. It is the everyday work that falls to trial coordinators, data managers, and clinical operations teams: choosing the right questionnaire for the population, capturing baseline context so scores mean the same thing across sites, and making sure the data arrive in a form clinicians and statisticians can trust.
Where PROM use typically breaks down
Three practical gaps show up again and again. First, instrument selection that does not match the patient population. An instrument that works for later-stage patients may be blind to the subtle functional changes in an earlier-stage cohort. Second, inconsistent domain and subscale reporting. Studies that publish only composite scores remove the signal that would explain why a score changed. Third, missing laterality context. If a trial does not document which eye was treated or which eye is better-seeing, the same PROM score can mean different things for different participants.
- Ceiling effects in early-stage cohorts that preserve visual acuity
- Composite-only reporting that hides which functional domains moved
- Insufficient documentation of treated-eye and fellow-eye status
These are not academic quibbles. They shape whether an efficacy signal can be pooled across sites, whether subgroup analyses are meaningful, and whether regulators or guideline authors can synthesize the evidence. A high-level PROM score without context is often noise rather than evidence.
What this means for trial workflows
The consequence lands on operations in three ways. One, screening and baseline capture become more complex because the team must collect and preserve additional context about vision status, lighting or contrast sensitivity, and which eye is functionally dominant. Two, follow-up cadence and question content need to vary by participant. A participant with intermediate AMD and preserved acuity requires different items to detect change than one with neovascular disease. Three, data that arrive as isolated scores force manual reconciliation between PROMs, clinical measures, and the trial database, a slow, error-prone process.
All three pressure points increase workload and create audit risk. If a regulator or a pooled meta-analysis asks for domain-level results or treated-eye documentation and the study cannot provide them, the trial’s contribution to evidence synthesis is diminished.
Questions to ask before site activation
Trial executives do not need a methods seminar. They need a short list of questions to ask their teams before launch. Does the selected PRO instrument match the functional domains likely to change in this population? Will subscales and domain scores be reported, or only composite totals? How will baseline visual function be captured and stored so subgroup comparisons are possible? Is laterality documented (better-seeing eye, treated eye, fellow eye) and linked to each PROM response? How will the trial handle participants whose vision changes asymmetrically over time?
These questions frame the operational work that follows. If the answers are vague, expect downstream friction when statisticians try to model treatment effects or when sponsors ask whether a measured PROM change is clinically meaningful.
A working approach treats PRO collection as part of the per-patient timeline, not an isolated questionnaire. That means capturing baseline context at enrollment, tailoring the items that matter for that patient, and scheduling follow-ups relative to each participant’s enrollment date. It also means flagging specific item responses for timely clinical review when they indicate deterioration. The technical details of how to implement this vary, but the operational picture is straightforward: each participant has their own clock, their own risk signals, and their own reporting context.
When teams design workflows this way, PROMs stop being post hoc decorations and start being usable endpoints. They align with clinical measures, inform safety monitoring, and produce domain-level data that can be pooled across studies.
How communication systems can reduce the burden
Automated, channel-flexible outreach helps keep PROM collection complete and contextual. Voice-first surveys reach older participants and those without smartphones; text messaging can be used for short reminders; secure messaging can carry longer questionnaires or clinician follow-up prompts. The point is removing the manual steps that cause missing baseline context, inconsistent subscale capture, and lost laterality documentation.
When communications are tied to the per-participant timeline, they can prompt enrollment-time baseline items, nudge participants for scheduled subscale assessments, and escalate concerning item-level responses to the clinical team. That alignment reduces manual reconciliation work and helps preserve the interpretability of PROs.
We see this pattern often in trial operations: clear definitions up front and workflows that capture context at enrollment save weeks of cleaning and rework later. More on voice-first and hybrid PRO collection is here.
At the executive level the takeaway is simple. PROM selection and reporting are governance issues as much as measurement issues. Ask the right questions before site activation, make baseline and laterality reporting non-negotiable, and treat PRO collection as a per-participant workflow rather than a one-off survey. Those changes make the difference between PROMs that confirm what the clinical data show and PROMs that add confusion to the dossier.
Related coverage: Study Finds a Need for Better Patient-Reported Outcome Measures in AMD – Review of Optometry